QUEST (12+ years)

DUPIXENT offers rapid breathing relief patients can feel as early as Week 2. Approximately 72% of the total FEV₁ improvement (470 mL improvement at Week 52 from baseline FEV₁ of 1.78 L) was seen at Week 2 in patients taking DUPIXENT 200 mg Q2W + SOC (n=264) (baseline blood EOS ≥300 cells/μL, QUEST, secondary endpoint).^1,10,11

A 320 mL improvement from baseline in pre-bronchodilator FEV₁ was seen at Week 12 with DUPIXENT 200 mg Q2W + SOC (n=631) vs 180 mL with placebo + SOC (n=317) (LSM difference: 140 mL [95% CI: 80, 190 mL]) (ITT population, QUEST, primary endpoint).^1,9

In QUEST, a significant difference from placebo + SOC was not observed at 12 weeks in change in pre-bronchodilator FEV₁ in patients with baseline blood EOS ≥150 to <300 cells/μL taking DUPIXENT 300 mg Q2W + SOC and in patients with baseline blood EOS <150 cells/μL taking DUPIXENT 200 mg Q2W or 300 mg Q2W + SOC.¹